Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients With Refractory Hematologic Malignancies

BACKGROUND: XL119 is a water-soluble derivative of rebeccamycin with dose-dependent myelosuppression as dose-limiting toxicity in phase 1 studies of solid tumors. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of XL119 in patients with advanced myelodysplastic s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Borthakur, Gautam, Alvarado, Yesid, Ravandi-Kashani, Farhad, Cortes, Jorge, Estrov, Zeev, Faderl, Stefan, Ivy, Percy, Bueso-Ramos, Carlos, Bekele, B. Nebiyou, Giles, Francis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126069/
https://ncbi.nlm.nih.gov/pubmed/18473351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23559
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia